NCIt definition : A humanized, afucosylated monoclonal antibody created using the proprietary, sugar-engineered
antibody (SEA) platform and directed against the tumor-associated antigen (TAA) human
B-cell maturation antigen (BCMA; TNFRSF17), with potential immunoadjuvant activity.
Upon administration, the anti-BCMA antibody SEA-BCMA targets and binds to BCMA expressed
on tumor cells. When administered with antibody-coupled T-cell receptor (ACTR)-expressing
T-cells, the ACTR-expressing T-cells bind, with high affinity, to the anti-BCMA antibody
SEA-BCMA. This activates the ACTR T-cells and the T-cells induce specific cytotoxic
T-lymphocyte (CTL)-mediated cytotoxicity toward BCMA-expressing tumor cells. BCMA,
a cell surface protein and member of the tumor necrosis factor (TNF) receptor superfamily
that is specifically overexpressed on malignant plasma cells, plays a key role in
promoting plasma cell survival.;
UNII : 3C28VJ95EV;
CAS number : 2115084-53-0; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 2115084-53-0
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
Semantic type(s)